Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Eli Lilly already posted preliminary data showing its obesity drug, Zepbound topped Novo Nordisk’s Wegovy on measures of weight loss in a head-to-head clinical trial. More detailed results ...

The first truly revolutionary oral drug for obesity, made by Eli Lilly, may soon be on the way. Skip to ... The two decisions build on the Lilly 30x30 program that was launched the year before ...

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to ... Lilly's Gimeno says the Verve-102 program, ... Obesity-related cancer deaths more than ...

Some of the potential iterations of delivery methods Eli Lilly considered for orforglipron, at Eli Lilly’s headquarters in Indianapolis on March 31. The ultimate form has yet to be finalized.